Josh Enomoto

Josh Enomoto

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

3 AI Stocks to Bet On for Market-Crushing Returns

Although AI stocks are incredibly popular, some enterprises may be overvalued. These ideas may offer better prospects.

3 Dividend-Paying ETFs to Secure Your Passive Income Stream

Passive income and ETFs represent two compelling market concepts. Why not bring the two together with dividend-paying ETFs?

3 Hypergrowth Stocks That Speculators Should Keep Tabs On

While a high-risk proposition, these hypergrowth stocks can potentially bring enormous returns in a short period of time.

7 Risk-On Stocks to Buy as Rate Cut Fervor Intensifies

The Federal Reserve may be on the cusp of issuing lower interest rates. These risk-on stocks might benefit from the change.

INTC Stock: Intel Appoints New Head of Foundry Manufacturing

Although Intel has been struggling in recent years, it hopes that new leadership changes will spark upward movement in INTC stock.

CREV Stock Pops as Carbon Revolution Snags Chevrolet Supply Deal

With Carbon Revolution’s advanced lightweight wheels offered as an option for the upcoming Corvette ZR1, CREV stock soared in response.

Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem

A compelling hidden-gem opportunity, Zai Lab’s groundbreaking cancer therapeutic and discounted valuation could drive up ZLAB stock.

Why Is Predictive Oncology (POAI) Stock Up 70% Today?

Predictive Oncology’s AI-driven platform demonstrated predictive utility in oncology, thereby providing credibility to POAI stock.

3 Stocks to Sell as Biden’s Reelection Bid Comes to an End

With Donald Trump having a more straightforward road to the White House, certain entities may become stocks to sell.

The 3 Best ETFs to Buy Now for AI and Robotics Exposure

While the automation sector is enticing, it’s been quite risky recently. Here are AI and robotics ETFs to even out the exposure.